- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00509249
Aflibercept in Treating Patients With Myelodysplastic Syndromes
A Phase II Study of VEGF Trap (NSC 724770) in Patients With MDS
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
OBJECTIVES:
I. To determine the antitumor activity of aflibercept as assessed by the hematological response rate.
II. To determine overall and progression-free survival in patients with myelodysplastic syndromes.
III. To assess hematologic improvement and time to leukemic transformation. IV. To assess the toxicity profile of aflibercept in this patient population. V. To perform correlative studies to better understand the ability of aflibercept to reach and modulate its respective targets.
OUTLINE: This is a multicenter study.
Patients will receive aflibercept IV over 1 hour on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
Blood and bone marrow samples will be obtained periodically for pharmacokinetic and biomarker correlative studies. Pharmacokinetic analysis by ELISA; anti-aflibercept antibody measurements; analysis of VEGF and VEGFR expression; and analysis of gene expression by quantitative PCR will be conducted. The effect of aflibercept on apoptosis and proliferation of CD34+ cells will also be analyzed by flow cytometry based assays.
After completion of study treatment, patients are followed periodically.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
California
-
Duarte, California, United States, 91010
- City of Hope Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Patients must have histologically or cytologically confirmed myelodysplastic syndromes (MDS), including any of the following:
- Secondary MDS
- MDS/myeloproliferative disorders (MPD) (e.g., chronic myelomonocytic leukemia or atypical chronic myeloid leukemia)
- IPSS scores of 0.5 or greater (≥ INT-1) OR transfusion dependent despite use of growth factors
- No more than 20% blasts in the marrow
- Patients who have not responded after 3 courses of hypomethylating agents (azacitidine or decitabine) OR; who are unable to tolerate hypomethylating agents OR who refused to receive hypomethylating agents are eligible for this study
- ECOG performance status ≤ 2 (Karnofsky ≥ 60%)
- Total bilirubin ≤ 1.5 x upper limit of normal (ULN)
- AST/ALT ≤ 2.5 x ULN
- Creatinine ≤ 1.5 x ULN OR creatinine clearance ≥ 60 mL/min
- Urine protein:creatinine ratio < 1 OR urine protein < 500 mg by 24-hour urine collection
- PT INR ≤ 1.5
Patients with PT INR > 1.5 on full-dose anticoagulants (e.g., warfarin) are eligible provided both of the following criteria are met:
- Patient has an in-range INR (usually between 2 and 3) and is on a stable dose of oral anticoagulant or low molecular weight heparin
- Patient has no active bleeding or pathological condition that carries a high risk of bleeding (e.g., tumor involving major vessels or known varices)
- Not pregnant or nursing
- Fertile patients must use effective contraception during and for at least 6 months after completion of study treatment
- Prior DNA-demethylating agent therapy or lenalidomide therapy allowed
- Prior treatment with other molecular agents, such as thalidomide, valproic acid, or imatinib mesylate allowed
Exclusion Criteria:
- Evidence of active malignancies other than squamous cell or basal cell carcinoma of the skin
- Known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to agents used in the study
- Serious or non-healing wound, ulcer, or bone fracture
- History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 28 days
- Significant traumatic injury within the past 28 days
Clinically significant cardiovascular disease, including any of the following:
- History of cerebrovascular accident (CVA) within the past 6 months
- Uncontrolled hypertension, defined as blood pressure > 150/100 mm Hg or systolic BP > 180 mm Hg if diastolic blood pressure < 90 mm Hg (on at least 2 repeated determinations on separate days) within the past 3 months
- Myocardial infarction or unstable angina within the past 6 months
- New York Heart Association class III or IV congestive heart failure, serious cardiac arrhythmia requiring medication, or unstable angina pectoris within the past 6 months
- Clinically significant peripheral vascular disease within the past 6 months
- Pulmonary embolism, deep vein thrombosis (DVT), or other thromboembolic event within the past 6 months
- Evidence of bleeding diathesis or coagulopathy
- Concurrent uncontrolled illness including, but not limited to, ongoing or active infection or psychiatric illness/social situation that would limit compliance with study requirements
- Prior cytotoxic chemotherapy for MDS
- Molecular therapy or immunosuppressive agents (including steroids) within the past 3 weeks
- Other prior antiangiogenesis agents
- Coronary artery bypass graft (CABG) within the past 6 months
- Valproic acid should be discontinued at least 24 hours before aflibercept administration, unless needed for seizure control
- Major surgical procedure or open biopsy within the past 28 days
- Core biopsy (other than bone marrow biopsy) within the past 7 days
- Anticipation of need for major surgical procedures during the course of the study
- Patients may not be receiving any other investigational agents
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm I
Patients will receive aflibercept IV at 4 mg/kg over 1 hour on day 1.
Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
|
Correlative studies
Correlative studies
Other Names:
Given IV
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Hematological Response Rate
Time Frame: Up to 3 years
|
Complete Response (CR): repeat bone marrow (BM) shows <5% myeloblasts, and peripheral blood values lasting ≥ 2 months of hemoglobin (hgb) (>110 g/L), neutrophils (≥1.0x10^9/L), platelets (≥100x10^9/L), blasts (0%) and no dysplasia.
Partial Response (PR): same as CR for peripheral blood except BM shows blasts decrease by ≥ 50% but still > 5% or a less advanced FAB classification from pretreatment.
Hematological response=CR+PR.
|
Up to 3 years
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Neoplasms by Histologic Type
- Neoplasms
- Disease
- Bone Marrow Diseases
- Hematologic Diseases
- Precancerous Conditions
- Leukemia, Myeloid
- Syndrome
- Myelodysplastic Syndromes
- Leukemia
- Preleukemia
- Leukemia, Myelomonocytic, Chronic
- Leukemia, Myelomonocytic, Juvenile
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Myeloproliferative Disorders
- Myelodysplastic-Myeloproliferative Diseases
- Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
- Physiological Effects of Drugs
- Antineoplastic Agents
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Aflibercept
- Endothelial Growth Factors
Other Study ID Numbers
- NCI-2009-00180
- N01CM62209 (U.S. NIH Grant/Contract)
- PHII-73
- CDR0000558101 (Registry Identifier: PDQ (Physician Data Query))
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Myelomonocytic Leukemia
-
M.D. Anderson Cancer CenterRecruitingMyelodysplastic Syndrome | Recurrent Chronic Myelomonocytic Leukemia | Recurrent Myelodysplastic Syndrome | Chronic Myelomonocytic Leukemia-1 | Chronic Myelomonocytic Leukemia-2 | Chronic Myelomonocytic Leukemia-0United States
-
Mayo ClinicRecruitingRecurrent Chronic Myelomonocytic Leukemia | Refractory Chronic Myelomonocytic LeukemiaUnited States
-
M.D. Anderson Cancer CenterRecruitingChronic Myelomonocytic Leukemia | Myelodysplastic/Myeloproliferative Neoplasm | Chronic Myelomonocytic Leukemia-1 | Chronic Myelomonocytic Leukemia-2United States
-
Humanigen, Inc.CompletedChronic Myelomonocytic Leukemia (CMML)United States
-
Gustave Roussy, Cancer Campus, Grand ParisRecruitingMyelomonocytic LeukemiaFrance
-
University of UtahCelgeneCompletedChronic Myelomonocytic LeukemiaUnited States
-
Arbeitsgemeinschaft medikamentoese TumortherapieCelgene CorporationUnknownChronic Myelomonocytic LeukemiaAustria
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedChronic Myelomonocytic Leukemia | Chronic Myelogenous LeukemiaUnited States
-
Groupe Francophone des MyelodysplasiesJanssen-Cilag Ltd.CompletedChronic Myelomonocytic LeukemiaFrance
-
H. Lee Moffitt Cancer Center and Research InstituteIncyte CorporationCompletedMyelomonocytic LeukemiaUnited States
Clinical Trials on laboratory biomarker analysis
-
Children's Oncology GroupNational Cancer Institute (NCI)Completed
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Active, not recruitingLeukemia | Acute Lymphoblastic Leukemia | Acute Promyelocytic LeukemiaUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedUntreated Adult Acute Lymphoblastic Leukemia | Untreated Childhood Acute Lymphoblastic LeukemiaUnited States, Canada, Australia, New Zealand, Puerto Rico, Switzerland
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedChildhood Acute Lymphoblastic Leukemia in Remission | Recurrent Childhood Acute Lymphoblastic LeukemiaUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)CompletedLung CancerUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Completed
-
Children's Oncology GroupNational Cancer Institute (NCI)WithdrawnClear Cell Renal Cell Carcinoma | Rhabdoid Tumor of the Kidney | Congenital Mesoblastic Nephroma | Childhood Kidney NeoplasmUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)WithdrawnBreast Carcinoma | BRCA1 Mutation Carrier | BRCA2 Mutation CarrierUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedWilms Tumor and Other Childhood Kidney TumorsUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedChildhood Acute Monoblastic Leukemia (M5a) | Childhood Acute Monocytic Leukemia (M5b) | Childhood Acute Myeloblastic Leukemia Without Maturation (M1) | Childhood Acute Myelomonocytic Leukemia (M4) | Childhood Acute Myeloid Leukemia/Other Myeloid MalignanciesUnited States